

# Alzheimer's Disease

CNS Block

---

# Objectives



Upon completion of this lecture, the students should be able to:

- Have an overview of neurodegenerative disorders
- Understand the role of amyloid beta 40-42 residue peptide in Alzheimer's disease
- Get an idea of the diagnosis and therapeutic approaches to treat these disorders

# Neurodegenerative Diseases



- Diseases of gray matter characterized principally by the progressive loss of neurons
- The pattern of neuronal loss is selective affecting one or more groups of neurons leaving the others intact
- The diseases arise without any clear inciting event in patients without previous neurological deficits

# Neurodegenerative Diseases



- A common theme is the development of protein aggregates that are resistant to normal cellular mechanisms of degradation
- The aggregated proteins are generally cytotoxic

# Alzheimer's Disease



- A degenerative disease with the prominent involvement of the **cerebral cortex**
- Its principal clinical manifestation is **dementia**
  - Dementia is the progressive loss of cognitive function independent of the state of attention
- Patients rarely become symptomatic before 50 yr. of age but the **incidence of disease rises with age**

# Alzheimer Disease




- The disease becomes apparent with:
  - Gradual impairment of higher intellectual function
  - Alterations in mood and behavior
  - Progressive disorientation
  - Memory loss
- In 5-10 yrs, the patient becomes profoundly disabled, mute and immobile
- Most cases are sporadic
- At least 5-10% are familial

# Diagnosis



- Combination of clinical assessment and radiologic methods
- Pathologic examination of brain tissue is necessary for definitive diagnosis
- Major microscopic abnormalities include: neuritic plaques, neurofibrillary tangles and amyloid angiopathy


# Neuritic Plaques




- Spherical with 20-200  $\mu\text{m}$  in diameter
- Contain paired helical filaments as well as synaptic vesicles and abnormal mitochondria
- The amyloid core contains several abnormal proteins
- The dominant component of the plaque core is **A $\beta$** , a peptide derived from a larger molecule, **amyloid precursor protein (APP)**




# Neuritic Plaques contd..



- The two dominant species of A $\beta$ , called A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> share an N-terminus and differ in length by two amino acids.
- Other less abundant proteins in the plaque:
  - Components of the compliment cascade
  - Proinflammatory cytokines
  - $\alpha_1$ -Antichymotrypsin
  - Apolipoproteins



# Neurofibrillary Tangles



- Bundles of filaments in the cytoplasm of neurons that displace or encircle the nucleus
- These filaments mainly contain:
  - Hyperphosphorylated forms of the **tau protein**
  - A protein that enhances microtubule assembly

# Amyloid Angiopathy



- Amyloid proteins build up on the walls of the arteries in the brain
- The condition increases the risk of hemorrhagic, stroke and dementia
- An almost invariable accompaniment of Alzheimer's disease but not specific for Alzheimer's

# Pathogenesis of Alzheimer's



- Still being intensively studied
- Strong correlation of number of neurofibrillar tangles with degree of dementia than neuritic plaques
- Biochemical markers correlated to degree of dementia include:
  - Loss of choline acetyl transferase
  - Synaptophysin immunoreactivity
  - Amyloid burden

# Pathogenesis of Alzheimer's



- Loss of synapses best correlates with severity of dementia
- The A $\beta$  peptide forms  $\beta$ -pleated sheets and aggregates
- Resistant to degradation
- Elicits a response from astrocytes and microglia
- Can be directly neurotoxic




**A $\beta$  is a critical molecule in the pathogenesis of Alzheimer's disease**

# A $\beta$ Peptides



- Derived from the processing of APP
- APP is a protein of uncertain cellular function
- It is synthesized with a single transmembrane domain and expressed on the cell surface

# Two pathways for APP processing





# Mechanism of amyloid generation




- APP has potential cleavage sites for three distinct enzymes ( **$\alpha$ ,  $\beta$ , and  $\gamma$ -secretases**)
- The  $A\beta$  domain extends from the extracellular side of protein into the transmembrane domain
- When APP is cleaved by  $\alpha$ -secretase , subsequent cleavage by  $\gamma$ -secretase does not yield  $A\beta$


# Mechanism of amyloid generation



- Cleavage by  $\beta$ -secretase followed by  $\gamma$ -secretase results in production of  $A\beta$
- $A\beta$  can then aggregate and form fibrils




# Accumulation of A $\beta$ protein




- Accumulation of A $\beta$  protein affects neurons and neuronal function:
  - Small aggregates of A $\beta$  alters neurotransmission
  - Aggregates can be toxic to neurons and synaptic endings
  - Larger deposits (plaques) also cause neuronal death
  - Elicit a local inflammatory response leading to further cell injury

# The Tau Protein



- Presence of  $A\beta$  causes hyper-phosphorylation of tau protein in neurons
- This leads to redistribution and aggregation of tau protein into tangles in neurons (from axon into dendrites and cell body)
- The process results in neuronal dysfunction and cell death

# A $\beta$ and Tau may both contribute to the pathogenesis of Alzheimer's Disease



# Genetics of Alzheimer's



- Mutations in APP gene
- Mutations in  $\gamma$ -secretase (presenilin-1 or presenilin-2)
- Both lead to early onset of familial Alzheimer's disease due to high rate of  $A\beta$  accumulation
  
- Alzheimer's occurs in most patients with Down's syndrome (trisomy 21) beyond 45 years of age
- The gene encoding APP is located in chromosome 21
- Due to APP gene dosage effects

# Genetics of Alzheimer's



- Genes associated with typical, sporadic Alzheimer's disease are being identified
- This may provide new clues to pathogenesis of the disease



# Genetics of Alzheimer's



Chromosome	Gene	Consequences
21	Amyloid Precursor Protein (APP)	Early onset FAD Increased A $\beta$ production
14	Presenilin-1 (PS1)	Early onset FAD Increased A $\beta$ production
1	Presenilin-2 (PS2)	Early onset FAD Increased A $\beta$ production
19	Apolipoprotein E (ApoE)	Increased risk for development of AD Decreased age at onset of AD

# Treatment of AD



- Currently, no effective treatment for AD
- regulating neurotransmitter activity e.g.,  
Enhancing cholinergic function improves AD
- Epidemiological studies showed that treatment with NSAIDs decreases the risk for developing AD. Unfortunately, clinical trials of NSAIDs in AD patients have not been very fruitful.

# Treatment of AD contd..



- Proinflammatory responses may be countered through polyphenols (flavonoids). Supplementation of these natural compounds may provide a new therapeutic line of approach to this brain disorder.

# Treatment of AD contd..



- Cellular therapies using stem cells offer great promise for the treatment of AD
- Stem cells offer
  1. Cellular replacement and/or provide environmental enrichment to attenuate neurodegeneration.
  2. Neurotrophic support to remaining cells or prevent the production or accumulation of toxic factors that harm neurons.

# Continued Research on AD



- The small aggregates of  $A\beta$  and larger fibrils are directly neurotoxic
- They can elicit oxidative damage and alterations in calcium homeostasis
- How  $A\beta$  is correlated to neurodegeneration in AD? How it is linked to tangles and hyperphosphorylation of tau protein?
- All remain open questions

# Take home message



- Neurodegeneration is progressive loss of structure and function of neurons including neuronal death
- Amyloid protein forms insoluble fibrous aggregates in neurons leading to Alzheimer's disease
- Deposition of amyloid interferes with normal cellular function resulting in loss of function and cell death
- The dominant component of amyloid plaque that accumulates in Alzheimer's disease is amyloid  $\beta$  42 ( $A\beta$ 42) peptide

# Further reading



- Illustrated Reviews of Biochemistry by Lippincott 4<sup>th</sup> edition (pp21-22 ).
- Fundamentals of Biochemistry by Voett and Voett (pp 170-174)